<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002096</url>
  </required_header>
  <id_info>
    <org_study_id>059E</org_study_id>
    <secondary_id>ICM 1776</secondary_id>
    <nct_id>NCT00002096</nct_id>
  </id_info>
  <brief_title>A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine</brief_title>
  <official_title>A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To determine whether there is a pharmacokinetic drug interaction between oral ganciclovir and
      oral zidovudine (AZT) and between oral ganciclovir and oral didanosine (ddI). To determine
      whether concurrent administration of probenecid affects the pharmacokinetics of oral
      ganciclovir. To obtain data on the short-term safety of oral ganciclovir administered
      concurrently with AZT, ddI, or probenecid in HIV-positive patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients currently on either AZT or ddI receive ganciclovir therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>24</enrollment>
  <condition>Cytomegalovirus Infections</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganciclovir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Concurrent Medication:

        Required:

          -  Concomitant AZT or ddI.

        Allowed:

          -  Probenecid.

          -  Aerosolized pentamidine.

        Patients must have:

          -  Asymptomatic HIV infection.

          -  CMV seropositivity or CMV culture positivity at present or at any time in the past.

          -  No history of CMV disease (e.g., retinitis, colitis) or any other AIDS-defining
             illness.

          -  Treatment with AZT or ddI for at least 1 month prior to study entry.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms and conditions are excluded:

          -  Uncontrolled diarrhea (three or more loose stools/day).

          -  Clinically significant gastrointestinal symptoms including persistent nausea or
             abdominal pain.

          -  AZT patients only:

          -  Deficiency in glucose-6-phosphate dehydrogenase.

          -  ddI patients only:

          -  Grade 2 or worse peripheral neuropathy.

        Concurrent Medication:

        Excluded:

          -  Combination antiretroviral therapy.

          -  G-CSF or GM-CSF.

          -  Acyclovir.

          -  Amphotericin B.

          -  Amikacin.

          -  Captopril.

          -  Carbamazepine.

          -  Cimetidine.

          -  Cyclosporine.

          -  Glutethimide.

          -  Gentamicin.

          -  Griseofulvin.

          -  Ibuprofen.

          -  Imipenem-Cilastatin.

          -  Lithium.

          -  Methicillin.

          -  Methotrexate.

          -  Naproxen.

          -  Pentamidine (Pentam 300) (Aerosolized drug permitted).

          -  Phenacetin.

          -  Phenobarbital.

          -  Phenytoin.

          -  Piroxicam.

          -  Ribavirin.

          -  Rifampin.

          -  Tobramycin.

          -  Vidarabine.

          -  Zalcitabine.

          -  Other investigational drugs.

        Patients with the following prior conditions are excluded:

          -  History of hypersensitivity to acyclovir or ganciclovir.

          -  AZT patients only:

          -  History of gout, uric acid, kidney stones, peptic ulcer or porphyria.

          -  ddI patients only:

          -  History of pancreatitis or alcoholism, or seizures within 6 months prior to study
             entry or prior need for anticonvulsant therapy.

        Prior Medication:

        Excluded:

          -  Combination antiretroviral therapy within 1 month prior to study entry.

        Required:

          -  AZT at 500 mg/day for at least 1 month prior to study entry (with 100 mg administered
             five times per day for at least 1 week prior to study entry). OR

          -  ddI at recommended dose for at least 1 month prior to study entry (with 250 mg
             administered every 12 hours for at least 1 week prior to study entry).

        History of alcoholism (in ddI patients).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ctr for Special Immunology</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown Univ Med Ctr</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ TX Galveston Med Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gaines K, Wong R, Jung D, Cimoch P, Lavelle J, Pollard R. Pharmacokinetic interactions with oral ganciclovir: zidovudine, didanosine, probenecid. Int Conf AIDS. 1994 Aug 7-12;10(1):7 (abstract no 004B)</citation>
  </reference>
  <verification_date>November 1993</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Didanosine</keyword>
  <keyword>Ganciclovir</keyword>
  <keyword>Drug Interactions</keyword>
  <keyword>Cytomegalovirus Infections</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Didanosine</mesh_term>
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

